Results 271 to 280 of about 84,355 (327)

CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma. [PDF]

Nat Commun
Luo CH, Hu LH, Liu JY, Xia L, Zhou L, Sun RH, Lin CC, Qiu X, Jiang B, Yang MY, Zhang XH, Yang XB, Chen GQ, Lu Y.   +13 more
europepmc   +1 more source

MS275 Inhibits Neuroblastoma Cell Growth by Mediating H3K27ac/PROX1 Axis In Silico and In Vitro

The FASEB Journal, Volume 39, Issue 13, 15 July 2025.
Our study demonstrates that MS275, a selective HDAC inhibitor, suppresses HDAC1/3 protein expression, leading to hyperacetylation of histone H3 at lysine 27 (H3K27ac) within the PROX1 promoter region (−608 to −508). This epigenetic modification upregulates PROX1 transcription, which subsequently modulates key cellular processes, including cell cycle ...
Chao Yuan, Chaoqun Li, Junwei Lu, Shengjie Liao, Runkun Wu, Duanzhuo Li, Mi Huang, Dacong Gong, Weibin Wu, Xin Yu, Shinuan Fei, Wenxia Si   +11 more
wiley   +1 more source

Non-coding RNAs in the spotlight of the pathogenesis, diagnosis, and therapy of cutaneous T cell lymphoma. [PDF]

Cell Death Discov
He X, Zhang Q, Wang Y, Sun J, Zhang Y, Zhang C.   +5 more
europepmc   +1 more source

Modified total skin electron treatment for a paraplegic patient

Journal of Applied Clinical Medical Physics, Volume 26, Issue 7, July 2025.
Abstract Total Skin Electron Therapy (TSET) has been a highly effective treatment for mycosis fungoides (MF). However, the standard TSET treatment requires the patient to stand upright in six different positions for an extended time period, which may not be possible for some patients.
Thomas Martin, Geoff Nelson, David Gaffney, Christian Dial, Martin Szegedi, Prema Rassiah   +5 more
wiley   +1 more source

Insidious Manifestations of Cutaneous T-cell Lymphoma. [PDF]

Clin Pract Cases Emerg Med
Cates AL, Kahn HP.
europepmc   +1 more source

Commissioning and clinical implementation of low dose dual‐field rotational TSET

Journal of Applied Clinical Medical Physics, Volume 26, Issue 7, July 2025.
Abstract Background Total skin electron therapy (TSET) is a specialized technique for treating cutaneous T‐cell lymphomas, such as mycosis fungoides. While traditional TSET regimens prescribe 30–36 Gy, low dose TSET at 12 Gy has gained attention due to its reduced toxicity.
Broderick Ivan McCallum‐Hee, Mounir Ibrahim, Godfrey Mukwada, Pejman Rowshanfarzad, Joshua Dass, Jude Dewitt, Robert Parin, Gregory Withey, Zaid Alkhatib   +8 more
wiley   +1 more source

The Role of the Gut Microbiome in Non-Hodgkin Lymphoma (NHL): A Focus on Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Cutaneous T-Cell Lymphoma, and NK/T-Cell Lymphoma. [PDF]

Cancers (Basel)
Łyko M, Maj J, Jankowska-Konsur A.
europepmc   +1 more source

First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

Cancer, Volume 131, Issue 13, 1 July 2025.
Abstract Background Indoleamine 2,3‐dioxygenase 1 (IDO1) is a heme‐containing enzyme that degrades tryptophan (Trp) to kynurenine (Kyn), which suppresses effector T cells and reduces antitumor activity. KHK2455 is a long‐acting selective IDO1 inhibitor that blocks the heme component of the IDO holoenzyme.
Timothy A. Yap, Olivier Rixe, Capucine Baldini, Ursa Brown‐Glaberman, Sergey Efuni, David S. Hong, Christophe Massard, Jameel Muzaffar, Andreea Varga, Emrullah Yilmaz, Yuta Ikawa, Lisa H. Shiue, Yi Liu, Matthew W. Hruska, Henry Zhao, Akihiro Tokunaga, Solmaz Sahebjam   +16 more
wiley   +1 more source

Sézary Syndrome—Eosinophilia Explained by a Blood Film

American Journal of Hematology, Volume 100, Issue 8, Page 1423-1424, August 2025.
Merel T. A. Soeterik, Joris Janssen, Leo M. Budel, Anton W. Langerak, Yorick Sandberg, Barbara J. Bain   +5 more
wiley   +1 more source

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report

Cancer Reports, Volume 8, Issue 7, July 2025.
ABSTRACT Background Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory pathways that cancer cells exploit to suppress T‐cell activation. Although immune‐related adverse events (irAEs) linked to ICI therapy are well documented and encompass dermatologic, endocrine, gastrointestinal, hepatic, and neurologic systems, ICI ...
Nidhi Kuchimanchi, Sai Gajula, Elizabeth M. Gaughan, Russell G. Witt   +3 more
wiley   +1 more source